Your browser is no longer supported. Please, upgrade your browser.
Novan, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own8.94% Shs Outstand133.69M Perf Week-15.79%
Market Cap208.85M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float130.56M Perf Month23.08%
Income-19.80M PEG- EPS next Q-0.06 Inst Own11.30% Short Float4.81% Perf Quarter233.89%
Sales5.20M P/S40.16 EPS this Y-137.60% Inst Trans45.68% Short Ratio0.28 Perf Half Y251.03%
Book/sh0.06 P/B26.67 EPS next Y53.10% ROA-49.90% Target Price- Perf Year255.48%
Cash/sh0.33 P/C4.85 EPS next 5Y- ROE276.20% 52W Range0.22 - 2.59 Perf YTD96.80%
Dividend- P/FCF- EPS past 5Y-5.90% ROI128.90% 52W High-38.22% Beta0.16
Dividend %- Quick Ratio5.60 Sales past 5Y112.90% Gross Margin- 52W Low644.19% ATR0.27
Employees42 Current Ratio5.60 Sales Q/Q0.00% Oper. Margin- RSI (14)49.07 Volatility14.38% 14.67%
OptionableNo Debt/Eq0.12 EPS Q/Q82.70% Profit Margin- Rel Volume0.29 Prev Close1.76
ShortableYes LT Debt/Eq0.11 Earnings- Payout- Avg Volume22.24M Price1.60
Recom2.00 SMA20-6.10% SMA5028.72% SMA200128.52% Volume6,550,800 Change-9.09%
Jan-06-20Downgrade Piper Jaffray Overweight → Neutral
Feb-25-21 07:30AM  
Feb-01-21 08:05AM  
Jan-29-21 04:05PM  
Jan-21-21 05:12AM  
Jan-19-21 09:00AM  
Jan-13-21 02:24PM  
Jan-08-21 09:00AM  
Dec-21-20 09:00AM  
Dec-15-20 09:00AM  
Dec-14-20 10:34AM  
Dec-03-20 04:12AM  
Nov-10-20 05:12AM  
Nov-04-20 07:30AM  
Oct-30-20 07:30AM  
Oct-21-20 09:00AM  
Oct-14-20 11:40AM  
Sep-24-20 07:05AM  
Sep-22-20 08:30AM  
Sep-14-20 09:05AM  
Sep-09-20 08:05AM  
Sep-04-20 10:17AM  
Sep-03-20 09:05AM  
Aug-31-20 08:05AM  
Aug-25-20 07:21AM  
Jul-30-20 06:50AM  
Jul-28-20 08:05AM  
Jul-23-20 08:05AM  
Jun-29-20 08:35AM  
Jun-26-20 08:21AM  
Jun-25-20 08:00AM  
Jun-24-20 08:15AM  
Jun-23-20 08:49AM  
Jun-17-20 05:30AM  
May-01-20 07:54AM  
Apr-30-20 04:05PM  
Apr-21-20 08:19AM  
Apr-20-20 04:05PM  
Apr-06-20 09:42AM  
Apr-03-20 08:15AM  
Apr-02-20 02:54PM  
Mar-31-20 10:51AM  
Mar-30-20 10:36AM  
Mar-26-20 04:05PM  
Mar-24-20 08:10AM  
Mar-23-20 08:15AM  
Mar-13-20 07:12AM  
Mar-11-20 09:54AM  
Mar-06-20 10:56AM  
Mar-03-20 04:05PM  
Feb-28-20 03:09PM  
Feb-27-20 11:20PM  
Feb-26-20 02:57PM  
Feb-24-20 02:59PM  
Feb-20-20 08:15AM  
Feb-06-20 08:30AM  
Jan-29-20 03:40AM  
Jan-06-20 10:06AM  
Jan-03-20 02:28PM  
Jan-02-20 04:15PM  
Dec-18-19 02:50PM  
Dec-06-19 12:29PM  
Nov-30-19 09:38AM  
Nov-19-19 06:19AM  
Oct-28-19 10:32AM  
Oct-22-19 09:54AM  
Oct-18-19 08:30AM  
Oct-08-19 08:30AM  
Sep-20-19 08:30AM  
Sep-11-19 04:05PM  
Sep-05-19 01:25PM  
Sep-03-19 04:05PM  
Aug-14-19 10:26AM  
Aug-13-19 04:15PM  
Aug-07-19 10:30AM  
Jul-24-19 08:30AM  
Jul-11-19 08:15AM  
Jun-27-19 06:47AM  
Jun-19-19 08:15AM  
Jun-13-19 09:15AM  
Jun-07-19 06:48AM  
Jun-06-19 04:15PM  
Jun-04-19 06:30AM  
May-31-19 04:15PM  
May-30-19 01:00PM  
May-16-19 08:26AM  
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.